This Kaplan-Meiers plot summarizes the in vivo data that emerged from a mouse study. Mice receiving allogeneic skin grafts were simultaneously treated with rapamycin (the standard of treatment for delaying host rejection), and either the vehicle, phosphate-buffered saline (PBS, negative control), or a negative control aptamer (PEG-cApt), or PEG-CCS13, or CD200Fc as a positive control for CD200R1 agonism. Each group consisted of 6 mice and the treatment was administered every 3 days for a period of 15 days until all the control grafts were completely rejected (i.e., by Day 15), at which point rapamycin treatment was ceased for the remaining PEG-CCS13 and CD200Fc treatment groups. As can be seen, the group treated with our lead aptamer, PEG-CCS13, exhibited a graft survival rate far superior to the controls, and comparable to the natural, soluble agonist fragment, CD200Fc.